Kornimate/medical-research-clean huggingface dataset:
site and mechanism(s) of expiratory airflow limitation in copd, emphysema and asthma-copd overlap

Conditions: COPD, Emphysema, Asthma COPD Overlap; Emphysema

Summary: the purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with copd, emphysema, and asthma-copd overlap with mild to severe expiratory airflow limitation. treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and pde type 4 inhibitor. in some cases, the patient may have had a history of asthma preceding the development of copd (asthma copd overlap).

the investigators are interested in determining the predominant site of expiratory airflow limitation including large central airways vs small peripheral airways/alveoli. in mild to moderate obstructive airways disease and emphysema, i believe routine spirometry including fev 1(l), fvc (l), and fev 1/fvc % may be normal, despite expiratory airflow limitation in lung peripheral airways. i also want to determine whether the mechanism(s) of expiratory airflow limitation are related to measured loss of lung elastic recoil or intrinsic obstruction of small peripheral airways or both. it is also important to determine the extent and distribution of emphysema using high resolution, thin section lung ct with voxel quantification. if available pathological analysis of lung surgical specimens and also formalin inflated lungs obtained at autopsy will also be studied. blood studies will include but not limited to cbc, serum ige, complete metabolic panel, and alpha 1 antitrypsin levels. extensive lung function testing will also include spirometry tests before and after inhaled albuterol bronchodilation, lung volumes measured in a plethysmograph, diffusing capacity, measurement of lung elasticity that requires placement of an esophageal balloon, measurement of airflow after breathing a mixture of 80% helium-20%oxygen for 7-10 minutes, and measurements of exhaled nitric oxide. cat scans of the lungs will be obtained to evaluate the presence, extent and distribution of emphysema and bronchiectasis. in some cases, bronchoscopy may be requested. the above tests may be uncomfortable but should cause no harm.

Eligibility criteria:
inclusion criteria: * asthma- copd overlap * emphysema in smokers with smoking history \> 15 pack years * copd/ bronchitis and bronchiectasis in smokers with smoking history * \>15 pack years exclusion criteria:other pulmonary or systemic diagnosis * non smokers * any other pulmonary diagnosis * pulmonary fibrosis

Keywords: copd, emphysema, asthma copd overlap
volar carbon plate effects on procedure time

Conditions: Radiation Exposure; Surgery; Radius Distal Fracture

Summary: radius distal end fractures are common orthopedic injuries. many methods have been described in the treatment of distal radius fractures. the fixation of radius distal end fracture with volar plate was first applied by ellis in 1965. over the years, ideas have been put forward on the materials used for plates and the radiolucent carbon fiber plates has been used. these plates cause less artifact in computed tomography (ct) and magnetic resonance examinations (mri), allow a better evaluation of the fracture, exhibit biomechanical characteristics close to the cortical bone, and do not cause a coldwedding in patients.

titanium alloy plates are frequently used materials in our current orthopedic surgery practices. the main goal during surgical treatment is to obtain an accurate and acceptable bone alignment. achieving this goal as soon as possible will reduce additional morbidity and mortality and increase the success of treatment. therefore, studies aiming to reduce the operation time come to the fore. when the literature is examined, there are limited number of studies on carbon plates. in these studies, it was reported that similar functional results were obtained with titanium alloy plates. although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. the increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. in our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. for this purpose, distal radius fractured patients applied to our clinic will be treated with titanium and carbon plates after the necessary randomization. after the tourniquet is applied, the time elapsed until the fixation is completed, the duration of scopy, and the number of scopy images taken will be recorded. in the follow-ups, the functional scores and radiological measurements of the patients will be made and the complications will be evaluated.

Eligibility criteria:
inclusion criteria: * radius distal simple intraarticular fractures * closed fractures exclusion criteria: * acompanying fracture at the same limb * open fractures * pathological fractures * the patients who don't want to be included in the study

Keywords: carbon plate radius distal radiation surgery
phase iv study of fda approved, once-daily gralise™(gabapentin) tablets for the treatment of postherpetic neuralgia

Conditions: Post Herpetic Neuralgia

Summary: study objective is to assess the safety and effectiveness of once- daily gralise in clinical practice

open label, single arm, 2wk titration, 6 wk stable dosing, 8 wk of total treatment, 1wk dose tapering

Eligibility criteria:
inclusion criteria: * men or women 18 years or older who are suffering from phn exclusion criteria: * patient is pregnant or a nursing mother * patient has hypersensitivity to gabapentin * patient has an estimated creatinine clearance of \<30 ml/min or is in hemodialysis

Keywords: phn post herpetic neuralgia shingles hz roster
study of endostatin combined with docetaxel in the treatment of advanced non-small cell lung cancer patients

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to examine the efficacy and safety of endostatin combined with docetaxel in advanced non-small-cell lung carcinoma (nsclc) patients failure to first-line or second-line chemotherapy.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed by the histologic, cytologic diagnosis of iiib (malignant hydrothorax or hydropericardium) or iv non-small cell lung cancer * ≥ 18 years old * patients who have received more than one regimen of platinum-based chemotherapy; patients who have received egfr monoclonal treatment could also be enrolled * at least one target lesion diameter spiral ct ≥ 1 cm, or the common ct ≥ 2 cm, and can be measured by imaging tools * have an interval of more than 4 weeks from the last chemo- or radio-therapy; 2 weeks from the last targeted therapy * ecog 0-2 * expected life time longer than 3 months * normal laboratory values: * leucocyte≥ 4×109/l * neutrophil≥ 1.5×109/l * platelet≥90×109/l * hemoglobin≥ 9g/l * alt and ast ≤3×uln (≤5×uln if liver metastasis) * serum creatinine\<1.5 mg/dl * bilirubin \<1.5×uln * no allergy to biological drug * sign the consent forms exclusion criteria: * patients who have previously received docetaxel or anti-vegf inhibitors * severe symptomatic heart disease * female patients during their pregnant and lactation period, or patients without contraception * severe uncontrolled infection * uncontrolled neurologic or psychiatric disease; uncontrolled primary or metastatic brain tumor * patients with other malignant tumor,except for basal cell carcinoma,squamous cell carcinoma and carcinoma in situ * patients have accepted other clinical trials

Keywords: objective response rate disease control rate disease free survival overall survival quality of live nonsmall cell lung cancer toxicity
comparison of ultrasound-guided corticosteroid injection versus corticosteroid injection and hydrodissection for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the objective of this study is to investigate the effect of ultrasound guided steroid injection versus ultrasound guided steroid hydrodissection to treat patients with cts.

this study was a prospective, randomized clinical trial. patients with cts were randomly treated with sonographically guided corticosteroid injection (group a); sonographically guided hydrodissection and corticosteroid injection (group b). boston carpal tunnel questionnaire, nerve conduction studies and vas pain score were performed on initial visit and after 6 weeks and 12 weeks .

Eligibility criteria:
inclusion criteria: clinical diagnosis of cts the diagnosis of cts was confirmed by electrophysiological tests. exclusion criteria: presence of thenar atrophy any accompanying orthopedic or neurologic disorders that could mimic cts such as cervical radiculopathy, polyneuropathy, proximal median nerve entrapment, or thoracic outlet syndrome prior steroid injection into the affected carpal tunnel within 6 months or ever received carpal tunnel surgery history of distal radius fracture pregnancy or lactation regular use of systemic nsaids ,corticosteroids or diuretics known allergy to corticosteroids and local anesthetics. impaired cognitive function -
study to evaluate the long term safety and efficacy of dwp16001 compared to placebo in the treatment of t2dm.

Conditions: T2DM (Type 2 Diabetes Mellitus)

Summary: the purpose of this study is evaluate the long term safety and efficacy of dwp16001 compared to placebo in the treatment of type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: 1. participated in the prior phase 3 study (protocol no: dw_dwp16001301) for meeting the inclusion criteria and completed the study 2. voluntarily decided to participate in the extension study and provided a written consent on the consent form exclusion criteria: 1. those who dropped out of the previously conducted phase 3 clinical trial (protocol no: dw_dwp16001301) 2. pregnant or lactating women or those who do not consent to the use of appropriate contraceptive methods during clinical trials appropriate method of birth control for you or your partner: you must agree to one of the following * either surgical sterilization (vasectomy, etc.) or insertion of an intrauterine device (copper loop, intrauterine hormone-containing system), or * a physical barrier method combined with either systemic hormonal contraceptives or spermicide, or * use of male condom combined with either cervical cap or diaphragm 3. in case the investigator judges that participation in this extended clinical trial is inappropriate in consideration of the 24-week observation progress in the previously conducted phase 3 clinical trial (protocol no: dw_dwp16001301)
hepasphere interventional therapy using digital subtraction angiography（dsa） for nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to evaluate the safety and efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa） for nasopharyngeal carcinoma.

by enrolling patients with nasopharyngeal carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of hepasphere interventional therapy using digital subtraction angiography （dsa） for nasopharyngeal carcinoma.

Eligibility criteria:
inclusion criteria: 1. age:18-80 2. karnofsky performance status \>60 3. diagnosis of nasopharyngeal carcinoma based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive interventional therapy 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except nasopharyngeal carcinoma 2. history of coagulation disorders or anemia

Keywords: nasopharyngeal carcinoma hepasphere
alice-regional anesthesia in italy: complications and outcomes

Conditions: Chronic Pain

Summary: regional anesthesia techniques, with administration of local anesthetics for neuraxial or peripheral route are now playing a central role in modern anesthesia and in particular in the control of postoperative pain. there are many review and meta-analyzes suggesting that a good pain control, and specifically loco regional analgesia, may improve the outcome of patients undergoing surgery. the control of acute post-operative pain is not the only challenge to be paid by anesthesiologists, because there is still much to be understood in relation to persistent post-surgical pain (ppp), and about the degree of influence that regional anesthesia plays in complete long-term functional recovery of patients. from the pathophysiological perspective there is not a precise definition of the mechanisms and risk factors that determine the onset of the persistent pain after surgery, but, more in general, it seems to be related to a malfunction of the mechanism of secondary hyperalgesia. regional anesthesia could play a key role, as the main determinant of chronic pain is acute post-operative pain. the techniques of regional anesthesia exert a powerful block at the peripheral level, potentially preventing the progression of central pain and the persistence of stimuli that can reach the central nervous system. in addition, during surgery, these techniques can reduce the metabolic alterations and the triggering mechanisms of local and systemic pro-inflammatory mediators' release. few perspective studies exist about the influence of regional anesthesia on long-term outcome and persistent pain after surgery. the objective of the investigators study is to assess in a prospective fashion the role of regional anesthesia/analgesia technique in preventing (or not) persistence pain occurrence after surgical interventions which are mostly associated to pain persistence, and understand if regional anesthesia provides advantages in other post-surgical outcomes.


Eligibility criteria:
inclusion criteria: * more than 18 ys old * informed consent exclusion criteria: * reintervention * asa (american society of anesthesiologists) status 4 and 5 * emergency surgery * no informed consent

Keywords: chronic pain
doxycycline pep and 4cmenb as a comprehensive prevention strategy in msm and tgw at high risk for bacterial stis within the swiss hiv cohort study

Conditions: Doxycycline STI PEP

Summary: the study aims at assessing effectiveness of offering event-driven doxy pep and 4cmenb immunization in msm/tgw at high sti risk. it plans to offer this sti prevention package to all msm/tgw in the shcs who are at risk of sti and then comparing 12-months sti incidence between those accepting and those not accepting the prevention package. the proposal further hosts two interesting sub-studies: one assessing potential effect of doxy pep on the microbiome and the other one assessing potential impact of doxy pep on tp, mg and ct resistance.


Eligibility criteria:
inclusion criteria: ≥ 18 years of age * participant in the shcs * on antiretroviral therapy with suppressed viral load for ≥ 3 months * msm or tgw * ≥ 1 bacterial sti (syphilis, ct, mg, or ng) within the past 3 years and/or reporting condomless sex with ≥ 1 occasional partner within the last 6 months * consenting for off-label use of doxycycline as pep and/or 4cmenb for the prevention of bacterial stis * no allergy or intolerance to doxycycline or 4cmenb * no other contraindication for doxycycline (e. g. co-medication) exclusion criteria: * not participating in the shcs

Keywords: docycycline postexposure propylaxis bacterial sexaully tarnsmitted diseases sexuylly transmitted diseases people living with hiv
a study of two forms of ganciclovir in the treatment of cytomegalovirus (cmv) of the eyes in patients with aids

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: to compare the time to progression of cytomegalovirus (cmv) retinitis among each of three doses of oral ganciclovir, as well as to intravenous therapy, when given as maintenance for 26 weeks. to compare the safety and tolerance among oral doses of ganciclovir at the study doses, as well as to intravenous therapy, when administered as maintenance for 26 weeks.

patients who have received anti-cmv therapy with intravenous ganciclovir for at least 4 weeks that resulted in stable retinitis are randomized to receive one of three doses of oral ganciclovir or intravenous ganciclovir for 26 weeks of maintenance.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * topical and ophthalmic nucleoside analogues. patients must have: * hiv positive. * no more than two episodes of cmv retinitis progression (relapse resulting in reinduction with intravenous anti-cmv therapy) since the original retinitis diagnosis. * currently stable retinitis. prior medication: allowed: * foscarnet prior to the 4 weeks of intravenous induction therapy. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * persistent or clinically significant diarrhea, nausea, or abdominal pain. * severe odynophagia. * other gastrointestinal (gi) symptoms or uncontrolled gi disease. * active cmv disease of the gi tract (e.g., cmv colitis, cmv esophagitis). * ocular media opacities (corneal, lenticular, or vitreal) that prevent ophthalmologic retinal assessments. * dementia, decreased mentation, or other encephalopathic signs and symptoms that would preclude informed consent or study compliance. concurrent medication: excluded: * acyclovir sodium (zovirax) by any route other than topical. * valacyclovir. * brovavir. * vidarabine. * amantadine hydrochloride. * cytarabine. * idoxuridine. * ribavirin. * interferon. * foscarnet (non-nucleoside pyrophosphate analogue). * cmv hyperimmune globulin. * soluble cd4. * trichosanthin (compound q). * imipenem-cilastatin. * isoprinosine. * levamisole. * other investigational drugs. patients with the following prior condition are excluded: history of hypersensitivity to acyclovir or ganciclovir. prior medication: excluded: * more than three induction regimens with intravenous anti-cmv therapy. * any prior oral ganciclovir.

Keywords: retinitis ganciclovir cytomegalovirus infections acquired immunodeficiency syndrome
hand hygiene intervention study in finnish garrison

Conditions: Infections

Summary: in this study the investigators aim to elucidate the possibility to reduce occurrence of infectious diseases in a garrison with enhanced and guided hand hygiene. the investigators will study occurrence and transmission of infections. in addition, the investigators will find out the causative agents of infections in a garrison with virological analyses of naso-pharyngeal and fecal specimens. the costs of lost service days and other expenses due to infectious diseases will be evaluated with a cost analysis study.


Eligibility criteria:
inclusion criteria: * willingness to attend to the study exclusion criteria: * skin diseases which prevent using hand disinfectants

Keywords: hand hygiene communicable diseases prevention
artificial tears to prevent nasolacrimal duct obstruction in patients treated with radioactive iodine for thyroid cancer

Conditions: Nasolacrimal Duct Obstruction; Thyroid Cancer

Summary: the association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. it is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. a recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. the purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.


Eligibility criteria:
inclusion criteria: 1. radio-iodine therapy for thyroid cancer 2. radioiodine therapy ≥150 mci 3. age 18 or older exclusion criteria: 1. use of eye drops, other than artificial tears 2. history of periocular trauma with tear duct involvement/lacrimal gland trauma 3. history of lacrimal drainage disease: canaliculitis, dacryocystitis 4. prior radiotherapy 5. current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel) 6. medical conditions that predispose to nld stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia) 7. nasolacrimal duct obstruction at baseline

Keywords: nasolacrimal duct obstruction artificial tears thyroid cancer
comparision of hydrodilatation results at different volumes in adhesive capsulitis by phases.

Conditions: Capsulitis of Shoulder; Hydrodilatation

Summary: adhesive capsulitis (ac) causes a global limitation of active and passive range of motion (rom) in the shoulder, with or without pain, and no other radiographic findings. the natural process is self-limiting, evolving in three or four phases. it is common in women around 50 years of age. diagnosis is based on clinical symptoms, with imaging tests being nonspecific. treatment options include physical therapy (pt), intra-articular corticosteroid injections, suprascapular nerve block (ssnb), and hydrodilatation (hd). the latter is useful for expanding and reducing inflammation of the joint capsule through insufflation with saline solution, anesthetics, and corticosteroids. objectives: to determine whether patients with ac, stratified by phase, who receive high-volume hd therapy achieve better outcomes in the shoulder pain and disability index (spadi), analgesic analogue scale (vas), and rom at the first, third, and sixth months of therapy compared to patients who receive low-volume hd. to determine whether there are differences in fst times and to determine mean axilar recess (ar) values. methods: a randomized, triple-blind, parallel-block clinical trial will be conducted in 64 patients with ac in phases 1 and 2, aged 30 to 70 years, with limited active and passive rom in two planes, and shoulder pain lasting more than 3 months. hd will be administered with volumes of 20 ml or 40 ml, followed by a physical therapy program. outcomes will be reviewed at the first, third, and sixth months of hd. variables collected will include spadi, vas, rom, lattinen assessment, ar size, and time to completion of pt


Eligibility criteria:
inclusion criteria: * ages between 30 and 70 years. * limited rom, both active and passive, in two planes. * shoulder pain lasting more than 3 months. exclusion criteria: * lidocaine + trial with improved rom. * conditions that preclude treatment (active cancer, tissue infection, oral anticoagulant use, cardiac arrhythmias, etc.) * previously receiving hd treatment in less than 1 year. * stage 0 or 3 ac. * non-adherence to the pt program, with attendance failures exceeding 20%. * presence of conditions that can cause similar symptoms, such as acromioclavicular osteoarthritis, labral injury, massive rotator cuff tear, or rheumatic diseases. * intra-articular corticosteroid injection in less than 2 months. * technique failure.

Keywords: adhesive capsulitis frozen shoulder hydrodilatation suprascapular nerve block